查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425023

小分子创新 CDMO 市场 - 2024 年至 2029 年预测

Small Molecule Innovator CDMO Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 152 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计小分子创新 CDMO 市场在预测期内将以 7.74% 的复合年增长率成长，市场规模从 2022 年的 511.65 亿美元增至 2029 年的 862.47 亿美元。

随着世界人口老化，针对老年人需求的医疗服务需求不断增加。此外，慢性病的盛行率显着增加，进一步增加了对创新小分子药物的需求。

此外，各国政府正在增加资源分配，以支持药物（包括小分子药物）的开发和製造。这是为了满足国家日益增长的医疗需求。例如，2023年6月，沙乌地阿拉伯公共投资基金（PIF）成立了医药投资公司（Lifera）。 Lifera 定位为商业规模的 CDMO，专注于生产救生和基本药物。这包括广泛的医疗解决方案，包括胰岛素、疫苗、血浆疗法、单株抗体、细胞和基因疗法以及创新小分子。这样营业单位的创建表明了我们对加速药物成长和应对慢性病扩散和人口老化带来的挑战的承诺。

慢性病增加

在全球范围内，癌症和糖尿病等各种健康状况的发生率不断上升，增加了对常用于治疗这些疾病的小分子药物的需求。现有资料显示该疾病在全球范围内的盛行率显着增加。

根据美国癌症协会的数据，在美国，2022 年新增癌症患者人数预计为 983,160 名男性和 934,870 名女性。这些数字强调了癌症作为健康问题的严重性，并强调了在医疗保健领域采取积极预防、诊断和治疗方法的必要性。

此外，这些统计数据凸显了製药领域，特别是小分子药物领域对解决方案的迫切需求。对这些药物的需求是因为它们具有降低成本、提供专业知识以及提高药物开发和製造过程的整体速度和效率的潜力。随着全球健康形势的发展，製药业面临着满足对有效治疗方法不断增长的需求的需要，这凸显了这些服务和医疗解决方案的重要性。

此外，不断增长的老年人口正在增加对创新医疗服务的需求，特别是在透过合约药物开发和受託製造厂商（CDMO）进行小分子药物创新领域。在美国，65岁及以上的人口数将大幅增加，到2020年将达到5,580万人（占总人口的16.8%）。这种人口变化显示了老龄化社会的明显趋势。随着人口持续老化，对满足老年人独特需求的医疗解决方案的需求不断增加。

中国小分子创新药CDMO市场可望稳定扩大。

该国提供端到端服务的合约开发和受託製造厂商（CDMO）数量显着增加，临床试验活性化的增加预计将支持市场成长。除此之外，中国的高疾病负担为满足药物研发和製造流程不断增长的需求提供了额外的动力。此外，由于本土专家数量众多以及临床试验机构的监管措施，中国是一个非常适合进行临床试验的国家。例如，中国国家药品监督管理局药品审查中心致力于以更低的成本提高临床试验研究的质量，并支持CDMO服务的发展。

根据世界卫生组织估计，由于预期寿命延长和出生率降低，未来中国人口老化预计将增加数倍。预计到 2040 年，这一数字将从 2019 年的 2.54 亿人增加到 4.02 亿人。这反映了对药物研发和药物开拓的需求不断增长，推动了小分子创新 CDMO 市场在预测期内的成长。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章小分子创新 CDMO 市场：副产品

  • 介绍
  • 小分子原料药
  • 小分子药物

第六章小分子创新 CDMO 市场：依客户类型

  • 介绍
  • 临床前
  • 临床
  • 商业的

第七章小分子创新 CDMO 市场：依治疗领域

  • 介绍
  • 循环系统疾病
  • 肿瘤学
  • 呼吸系统疾病
  • 神经病学
  • 代谢紊乱
  • 感染疾病
  • 其他的

第八章小分子创新 CDMO 市场：按地区

  • 介绍
  • 北美洲
    • 副产品
    • 依客户类型
    • 按治疗区域
    • 按国家/地区
  • 南美洲
    • 副产品
    • 依客户类型
    • 按治疗区域
    • 按国家/地区
  • 欧洲
    • 副产品
    • 依客户类型
    • 按治疗区域
    • 按国家/地区
  • 中东/非洲
    • 副产品
    • 依客户类型
    • 按治疗区域
    • 按国家/地区
  • 亚太地区
    • 副产品
    • 依客户类型
    • 按治疗区域
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • CatSci Ltd.
  • Eurofins Scientific
  • Lonza
  • Sai Life Sciences
  • Ardena
  • Recipharm
  • Cambrex
  • Merck Millipore
  • Catalent
  • AGC Pharma Chemicals Europe
简介目录
Product Code: KSI061616036

The small molecule innovator CDMO market is projected to grow at a CAGR of 7.74% during the forecast period thereby reaching a market size of US$86.247 billion in 2029 from an initial value of US$51.165 billion in 2022.

The increasing aging population globally is creating demand for healthcare services tailored to the needs of elderly individuals. Additionally, the prevalence of chronic ailments has seen a notable uptick, further fueling the demand for innovative small-molecule drugs.

Moreover, governments are increasingly allocating resources to support the development and manufacturing of pharmaceuticals, including small-molecule drugs. This is in response to the growing healthcare needs of their populations. For instance, the establishment of the pharmaceutical investment company (Lifera) by the Public Investment Fund (PIF) of Saudi Arabia on June 2023. Lifera is positioned as a commercial-scale CDMO with a focus on manufacturing life-saving and essential pharmaceutical products. This includes a diverse range of medical solutions such as insulins, vaccines, plasma therapeutics, monoclonal antibodies, cell and gene therapies, and innovative small molecules . The creation of such entities demonstrates a commitment to fostering the growth of the pharmaceutical and addresses the challenges posed by the surge in chronic diseases and the aging demographic.

Increasing cases of chronic ailments

Globally, the increasing incidence of various health conditions such as cancer and diabetes has led to a heightened demand for small-molecule drugs, which are commonly employed in the treatment of these ailments. The available data indicates a substantial rise in the prevalence of diseases worldwide.

In the United States, as indicated by the American Cancer Society, the estimated number of new cancer cases for the year 2022 stands at 983,160 for males and 934,870 for females. These figures underscore the significant impact of cancer as a prevalent health concern., This highlights the ongoing need for robust efforts in prevention, diagnosis, and treatment within the healthcare landscape.

Further, these statistics underscore the pressing need for pharmaceutical solutions, particularly in the realm of small-molecule drugs. The demand for these medicines is driven by their potential to reduce costs, provide access to specialized expertise, and enhance overall speed and efficiency in drug development and manufacturing processes. As the global health landscape evolves, the pharmaceutical industry faces the need to meet the growing demand for effective treatments, emphasizing the importance of such services and healthcare solutions.

Additionally, the growing elderly demographic is contributing to an increased need for novel healthcare services, specifically in the realm of small molecule innovation through Contract Development and Manufacturing Organizations (CDMOs). In the United States, the population aged 65 and older has undergone significant expansion, totalling 55.8 million individuals or 16.8% of the overall population in 2020. This demographic shift signals a clear trend toward an aging society. As people advance in age, there arises a growing demand for healthcare solutions that is meet the unique needs of the elderly population.

The China small molecule innovator CDMO market is predicted to expand steadily.

The rise in clinical trial activity with a significant increase in contract development & and manufacturing organizations (CDMOs) offering end-to-end services in the country is expected to boost market growth. In addition to this, the high disease burden in China provides further impetus to meet the growing demand for drug development and manufacturing processes. Furthermore, China is a highly preferred country for conducting clinical trials owing to its large pool of local experts and regulatory actions by clinical trial bodies. For instance- NMPA's Center for Drug Evaluation in China takes initiatives to improve the quality of clinical trial studies at low cost, supporting the development of CDMO services.

As per the estimates from WHO, the ageing population in China is expected to grow multifold in upcoming years attributed to longer life expectancy and declining fertility rates. By the year 2040, it is expected to reach 402 million people from 254 million people in 2019. This reflects the increasing demand for drug discovery and development, promoting the growth of the small molecule innovator CDMO market till the forecast period.

Market Key Developments

  • In January 2023, Lonza completed the expansion of its Solid Form Services Facility in Bend, USA. This expanded facility includes dedicated laboratory space designed to support biotech and midsize pharmaceutical companies in their early-stage compound development. It offers comprehensive support for solid form screening, characterization of small molecule active pharmaceutical ingredients (APIs), and early-stage crystallization process development.
  • In September 2022, WuXi STA, a subsidiary of WuXi AppTec, announced the opening of its new sterile lipid nanoparticle formulation facility. The integrated drug product platform CRDMO will offer various services. These include such as pre-formulation, formulation development, solid-state development, and clinical to commercial drug product manufacturing with a wide spectrum of drug delivery technologies.

Segmentation:

By Product

  • Small Molecule API
  • Small Molecule Drug Product

By Customer Type

  • Preclinical
  • Clinical
  • Commercial

By Therapeutic Area

  • Cardiovascular Disease
  • Oncology
  • Respiratory Disorders
  • Neurology
  • Metabolic Disorders
  • Infectious Disease
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • UK
  • France
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. SMALL MOLECULE INNOVATOR CDMO MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Small Molecule API
  • 5.3. Small Molecule Drug Product

6. SMALL MOLECULE INNOVATOR CDMO MARKET BY CUSTOMER TYPE

  • 6.1. Introduction
  • 6.2. Preclinical
  • 6.3. Clinical
  • 6.4. Commercial

7. SMALL MOLECULE INNOVATOR CDMO MARKET BY THERAPEUTIC AREA

  • 7.1. Introduction
  • 7.2. Cardiovascular Disease
  • 7.3. Oncology
  • 7.4. Respiratory Disorders
  • 7.5. Neurology
  • 7.6. Metabolic Disorders
  • 7.7. Infectious Disease
  • 7.8. Others

8. SMALL MOLECULE INNOVATOR CDMO MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product
    • 8.2.2. By Customer Type
    • 8.2.3. By Therapeutic Area
    • 8.2.4. By Country
    • 8.2.4.1. United States
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Product
    • 8.3.2. By Customer Type
    • 8.3.3. By Therapeutic Area
    • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Product
    • 8.4.2. By Customer Type
    • 8.4.3. By Therapeutic Area
    • 8.4.4. By Country
    • 8.4.4.1. United Kingdom
    • 8.4.4.2. Germany
    • 8.4.4.3. France
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Product
    • 8.5.2. By Customer Type
    • 8.5.3. By Therapeutic Area
    • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Israel
    • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Product
    • 8.6.2. By Customer Type
    • 8.6.3. By Therapeutic Area
    • 8.6.4. By Country
    • 8.6.4.1. Japan
    • 8.6.4.2. China
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Thailand
    • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisition, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. CatSci Ltd.
  • 10.2. Eurofins Scientific
  • 10.3. Lonza
  • 10.4. Sai Life Sciences
  • 10.5. Ardena
  • 10.6. Recipharm
  • 10.7. Cambrex
  • 10.8. Merck Millipore
  • 10.9. Catalent
  • 10.10. AGC Pharma Chemicals Europe